继与诺华公司进一步扩大软件协议后,Schrodinger Inc再次传来重磅利好消息。11月12日盘前,该股大涨10.59%,投资者对公司前景持看好态度。
根据Schrodinger Inc与诺华近期签订的研究合作与许可协议,诺华公司将把多个候选药物项目纳入其产品开发管线,由Schrodinger Inc利用其先进的计算药物发现平台进行研发。协议规定,Schrodinger Inc将获得15亿美元的预付款和里程碑付款,如果有任何药物最终成功商业化,还将从其净销售收入中获得中个位数至低两位数的特许权使用费。
此外,Schrodinger Inc还上调了本财年软件收入增长预期,由此前的6%-13%上调至8%-13%。分析人士认为,与诺华等巨头建立深度合作关系,必将进一步提升Schrodinger Inc在制药领域的影响力,有利于公司长期可持续发展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.